Researchers in the United States are testing a groundbreaking vaccine designed to prevent opioid overdoses, addressing a crisis that claims tens of thousands of lives annually.
The COVID-19 pandemic sparked intense debate on vaccines, marred by widespread misinformation that led platforms like YouTube to crack down on disinformation. Yet, vital research persists to combat other health threats. As reported by NBC News on October 2, 2021, the first doses of an experimental vaccine to prevent opioid overdoses have been administered.
This clinical trial involves volunteers with opioid addiction, monitored for about ten weeks by experts from the University of Minnesota's Medical School. Participants receive the vaccine followed by controlled, non-lethal opioid doses to evaluate its effectiveness.
The vaccine works by prompting the immune system to produce targeted antibodies, similar to traditional vaccines. Here, the focus is on oxycodone, a potent opioid painkiller. Importantly, it won't eliminate cravings or withdrawal symptoms—its goal is to protect against overdoses and severe brain damage.
Other institutions are developing vaccines against opioids like fentanyl. However, experts emphasize that vaccines alone won't solve this major public health crisis—effective addiction treatments, such as safer alternatives or therapies, are essential.
U.S. overdose statistics are alarming: In 2020, 93,331 people died, with 70% linked to opioids. In 2019, 1.6 million Americans struggled with opioid use disorder, often stemming from recreational use or painkiller prescriptions.
In France, a 2019 ANSM report noted opioid overdose hospitalizations rising from 15 to 40 per million inhabitants between 2000 and 2017, with deaths doubling over the same period.
